drugset / Trial / NCT01803308
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare the safety and tolerability of ascending doses of SB 9200 given for up to 14 days to subjects with chronic Hepatitis C infection.
Timeline
- Start
- 2013-03
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inarigivir soproxil | Small molecule | 100 mg | — |
| Subject | Inarigivir soproxil | Small molecule | 1500 mg | — |